Age Related Macular Degeneration News and Research RSS Feed - Age Related Macular Degeneration News and Research

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Omega-3 could supplement anti-VEGF treatment in AMD

Omega-3 could supplement anti-VEGF treatment in AMD

Pilot study findings suggest that taking omega-3 fatty acid supplements could increase the efficacy or reduce the needed frequency of anti-vascular endothelial growth factor treatment in patients with exudative age-related macular degeneration. [More]
‘Earliest’ characteristics presaging drusen-associated atrophy identified

‘Earliest’ characteristics presaging drusen-associated atrophy identified

Researchers have used spectral-domain optical coherence tomography to identify specific pathological changes that precede the development of drusen-associated atrophy in patients with age-related macular degeneration. [More]

Adaptive optics find reflectivity differences between drusen types in AMD

Adaptive optics provide insight into the differences in reflectivity between medium–large drusen and reticular pseudodrusen in patients with age-related macular degeneration, researchers report. [More]

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology. [More]
NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

Macular degeneration is a major cause of irreversible vision loss in the United States and around the world. As many as 11 million Americans have some form of macular degeneration. [More]
EyePromise® eye vitamins offers education guide to promote awareness on AMD

EyePromise® eye vitamins offers education guide to promote awareness on AMD

Due to the aging Baby Boomer population, AMD, or Age-related Macular Degeneration, is expected to double by the year 2020. [More]
Reversing effects of early stage age-related macular degeneration may be possible

Reversing effects of early stage age-related macular degeneration may be possible

A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity. [More]
Researchers identify molecular mechanisms that can prevent blindness, promote recovery from stroke

Researchers identify molecular mechanisms that can prevent blindness, promote recovery from stroke

Research led by Nicolas Bazan, MD, PhD, Boyd Professor, Ernest C. and Yvette C. Villere Chair of Retinal Degeneration Research, and Director of the Neuroscience Center of Excellence at LSU Health New Orleans, has discovered gene interactions that determine whether cells live or die in such conditions as age-related macular degeneration and ischemic stroke. [More]
Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

Hutchinson-Gilford Progeria Syndrome can be compared to normal aging, say scientists

In a new research study, scientists from Vision Genomics, LLC, Insilico Medicine, Inc., and Howard University showed that Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) is comparable to normal aging with respect to cellular signaling pathways, and that HGPS truly recapitulates the normal aging process. [More]
Tackling preventable blindness: a House of Commons reception review

Tackling preventable blindness: a House of Commons reception review

“Macular degeneration is not life threatening, but it is life changing,” these were the words of Michael Valenzia, of the Macular Society at the recent House of Commons Reception held by AMD Alliance International. [More]
Microscopic spheres of calcium phosphate linked to AMD development

Microscopic spheres of calcium phosphate linked to AMD development

Microscopic spheres of calcium phosphate have been linked to the development of age-related macular degeneration (AMD), a major cause of blindness, by UCL-led research. [More]
Tiny lumps of calcium phosphate may trigger age-related macular degeneration

Tiny lumps of calcium phosphate may trigger age-related macular degeneration

New research from scientists at the University of Maryland School of Medicine has found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD), a degenerative eye disease that can cause severe vision loss and blindness. [More]
Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years. [More]
Using HIV drugs to treat AMD: an interview with Dr Mark Young

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth. [More]
Scientific collaboration reveals encouraging insight on AMD disease

Scientific collaboration reveals encouraging insight on AMD disease

Insilico Medicine along with scientists from Vision Genomics and Howard University shed light on AMD disease, introducing the opportunity for eventual diagnostic and treatment options. [More]
Exudation-free period key to cataract surgery success in AMD

Exudation-free period key to cataract surgery success in AMD

Cataract surgery can benefit patients with exudative age-related macular degeneration previously treated with anti-vascular endothelial growth factors if they have been treated and are exudation-free for more than 12 months, study findings indicate. [More]

Optical coherence tomography methods comparable for AMD assessments

There is good accordance between spectral-domain and time-domain optical coherence tomography image assessments of eyes treated for neovascular age-related macular degeneration, show study findings. [More]

OCT enhances neovascular subtype detection in AMD

Researchers recommend the inclusion of optical coherence tomography anatomic classification with fluorescein angiography grading to identify initial neovascular lesion subtypes in newly diagnosed age-related macular degeneration. [More]
Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Scientists have developed a new light-sensitive film that could one day form the basis of a prosthetic retina to help people suffering from retinal damage or degeneration. Hebrew University of Jerusalem researchers collaborated with colleagues from Tel Aviv University and Newcastle University in the research, which was published in the journal Nano Letters. [More]